ANI Pharmaceuticals
ANIP Nasdaq· Pharmaceuticals
Last close · Oct 26, 2026
$72.60
KIRA · Stoqly’s AI analyst, in plain words
- ANI Pharmaceuticals had $883M of revenue in fiscal 2025, up 43.8% on the year before. Over five years, revenue changed +33.5% a year on average.
- Its operating margin was 12.6%, up 12.5 pts: of every 100 in sales, about 13 is left after running the business.
- ANI Pharmaceuticals made $78.3M of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew 28.8% a year.
- Free cash flow was $171M in fiscal 2025, 19.4% of revenue.
- ANI Pharmaceuticals returned $13.4M to shareholders in fiscal 2025, 8% of free cash flow. The diluted share count rose 9.9%.
- ANI Pharmaceuticals owes $23.7M more than it holds in cash, about 0.1 years of operating profit.
Market cap
$1.6B
P/E
15.7x
Revenue
$883M
Net income
$78.3M
Free cash flow
$171M
Operating margin
12.6%
ANI Pharmaceuticals in 30 seconds · fiscal 2025
Are sales growing?
+43.8%
Yes. Sales grew 43.8% last year.
Does it make a profit?
8.9%
A little. It keeps 8.9% of every sale as profit.
Does profit turn into cash?
19.4%
Yes. 19.4% of sales ends up as free cash.
Is debt under control?
0.1x
Yes. It could repay its debt with 0.1 years of operating profit.
How healthy are the accounts?
6 / 8
Mixed. It passes 6 of 8 health tests.
How is the share priced?
15.7x
One share costs 15.7 times its yearly profit per share. Typical for its sector: 28.4x.
What ANI Pharmaceuticals does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 27, 2026
- Legal name
- ANI PHARMACEUTICALS, INC
- CIK
- 0001023024
ANI Pharmaceuticals · ANIP
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $216M | $316M | $487M | $614M | $883M |
| Revenue growth | 3.7% | 46.4% | 53.9% | 26.2% | 43.8% |
| Operating margin | −18.4% | −11.2% | 9.7% | 0.1% | 12.6% |
| Net income | −$42.6M | −$47.9M | $18.8M | −$18.5M | $78.3M |
| Net margin | −19.7% | −15.1% | 3.9% | −3.0% | 8.9% |
| Diluted EPS | −$3.40 | −$3.05 | $0.85 | −$1.04 | $3.32 |
| Cash | |||||
| Cash from operations | $3.3M | −$31.2M | $119M | $64.0M | $185M |
| Capital expenditure | $2.6M | $8.9M | $8.9M | $16.2M | $13.8M |
| Free cash flow | $0.8M | −$40.1M | $110M | $47.8M | $171M |
| FCF margin | 0.4% | −12.7% | 22.6% | 7.8% | 19.4% |
| Dividends paid | $0.2M | $1.6M | $1.6M | $1.6M | $1.2M |
| Share buybacks | $0.9M | $2.0M | $5.0M | $11.0M | $12.2M |
| Share count change | 5.3% | 29.1% | 11.9% | 6.2% | 9.9% |
| Debt and strength | |||||
| Cash and short-term investments | $100M | $48.2M | $221M | $145M | $286M |
| Debt incl. finance leases | $287M | $287M | $286M | $319M | $309M |
| Shareholders' equity | $334M | $314M | $433M | $404M | $541M |
| Net debt / EBITDA | 25.1x | 11.0x | 0.6x | 2.5x | 0.1x |
| Current ratio | 3.7x | 3.5x | 3.6x | 2.7x | 2.7x |
| Interest coverage | −3.3x | −1.2x | 1.3x | 0.0x | 3.4x |
| Returns and quality | |||||
| Return on capital | −7.0% | −5.2% | 8.5% | 0.1% | 15.9% |
| Return on equity | −16.1% | −14.8% | 5.0% | −4.4% | 16.6% |
| Piotroski F-score | 4 | 3 | 7 | 4 | 6 |
| Altman Z'' | 2.3 | 2.2 | 3.8 | 2.0 | 3.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$15.5M
12 insiders
Of sales under plans
38%
$5.9M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
ANI Pharmaceuticals · ANIP
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| ANI Pharmaceuticals ANIP | $1.6B | 43.8% | 12.6% | 19.4% | 15.9% | 15.7x | 6 |
| Collegium Pharmaceutical COLL | $754M | 23.6% | 23.0% | 42.0% | 53.4% | 18.7x | 6 |
| Corcept Therapeutics CORT | $10.3B | 12.8% | 5.9% | 18.6% | 15.7% | — | 3 |
| Acadia Pharmaceuticals ACAD | $3.4B | 11.9% | 9.8% | 9.8% | — | 8.9x | — |
| Amphstar Pharmaceuticals AMPH | $1.1B | −1.7% | 19.5% | 16.8% | 9.9% | 15.1x | 6 |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
At $72.60 a share, the company is worth $1.6B: 15.7 times its earnings of the last four quarters.
ANI Pharmaceuticals grew sales faster than 4 of its 4 similar companies. Its P/E is higher than 2 of 3.
Source: SEC EDGAR XBRL filings (CIK 0001023024). Data updated October 22, 2026. For information only — not investment advice. Check the original filings before relying on any figure.